sensorineural hearing loss ototoxicity ototoxicity cisplatin Thai pediatric solid tumors long term outcome
Conditions
Interventions
Thai pediatric oncology patients who received cisplatin at the Department of Pediatrics, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand from January, 2007 to December, 201
Screening
Thai pediatric oncology patients who received cisplatin
Sponsors
none
Eligibility
Sex/Gender
All
Age
1 Years to 15 Years
Inclusion criteria
Inclusion criteria: 1.pediatric solid tumor patients including neuroblastoma, hepatoblastoma, osteosarcoma, and germ cell tumor who were younger than 15 years old and received cisplatin-based chemotherapy at the Department of Pediatrics, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand from January, 2007 to December, 2019, 2.Patients were evaluated baseline hearing with audiogram and/or auditory steady-state response (ASSR) pre- or within 1 month of initiation of cisplatin and were followed up the hearing test at least 2 sequential times.
Exclusion criteria
Exclusion criteria: Patients who had anatomical defect of ear and renal dysfunction before treatment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Severity of ototoxicity pre- or within 1 month of initiation of cisplatin and were followed up the hearing test at least 2 sequential times the Common Terminology Criteria for Adverse Events version 5 | — |
Secondary
| Measure | Time frame |
|---|---|
| Incidence of ototoxicity pre- or within 1 month of initiation of cisplatin and were followed up the hearing test at least 2 sequential times percent | — |
Countries
Thailand
Contacts
Public ContactKleebsabai Sanpakit
Department of Pediatrics, Siriraj hospital
Outcome results
None listed